Treatment of malignant mesothelioma with epirubicin and ifosfamide

M. D. Magri, S. Foladore, A. Veronesi, C. Serra, M. Nicotra, M. Tommasi, G. Grandi, S. Monfardini, C. Bianchi

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

From May 1988 to March 1990, 17 consecutive patients with histologically proven malignant mesothelioma were treated with epirubicin 75 mg/sqm i.v. on day 1 and ifosfamide 1.8 gr/sqm/day i.v. from day 1-5. Treatment was repeated every 3 weeks until progression. Fifty-three chemotherapy cycles were administered to the 17 patients treated (median, 3 cycles/patient). No complete responses, 1 partial response, 8 stable diseases and 8 progressions were noted. Toxocity was acceptable and no treatment-related deaths occurred. Actuarial median survival was 6 months. In this study, a combination of full doses of epirubicin and ifosfamide did not prove to be active in malignant mesothelioma.

Original languageEnglish
Pages (from-to)237-238
Number of pages2
JournalAnnals of Oncology
Volume3
Issue number3
Publication statusPublished - 1992

Fingerprint

Epirubicin
Ifosfamide
Chemotherapy
Progression
Cycle
Consecutive
Dose
Partial
Disease Progression
Therapeutics
Drug Therapy
Survival
Malignant Mesothelioma
Median

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Hematology

Cite this

Magri, M. D., Foladore, S., Veronesi, A., Serra, C., Nicotra, M., Tommasi, M., ... Bianchi, C. (1992). Treatment of malignant mesothelioma with epirubicin and ifosfamide. Annals of Oncology, 3(3), 237-238.

Treatment of malignant mesothelioma with epirubicin and ifosfamide. / Magri, M. D.; Foladore, S.; Veronesi, A.; Serra, C.; Nicotra, M.; Tommasi, M.; Grandi, G.; Monfardini, S.; Bianchi, C.

In: Annals of Oncology, Vol. 3, No. 3, 1992, p. 237-238.

Research output: Contribution to journalArticle

Magri, MD, Foladore, S, Veronesi, A, Serra, C, Nicotra, M, Tommasi, M, Grandi, G, Monfardini, S & Bianchi, C 1992, 'Treatment of malignant mesothelioma with epirubicin and ifosfamide', Annals of Oncology, vol. 3, no. 3, pp. 237-238.
Magri MD, Foladore S, Veronesi A, Serra C, Nicotra M, Tommasi M et al. Treatment of malignant mesothelioma with epirubicin and ifosfamide. Annals of Oncology. 1992;3(3):237-238.
Magri, M. D. ; Foladore, S. ; Veronesi, A. ; Serra, C. ; Nicotra, M. ; Tommasi, M. ; Grandi, G. ; Monfardini, S. ; Bianchi, C. / Treatment of malignant mesothelioma with epirubicin and ifosfamide. In: Annals of Oncology. 1992 ; Vol. 3, No. 3. pp. 237-238.
@article{0d7bc9b7247a452d8d622a546d5d6b75,
title = "Treatment of malignant mesothelioma with epirubicin and ifosfamide",
abstract = "From May 1988 to March 1990, 17 consecutive patients with histologically proven malignant mesothelioma were treated with epirubicin 75 mg/sqm i.v. on day 1 and ifosfamide 1.8 gr/sqm/day i.v. from day 1-5. Treatment was repeated every 3 weeks until progression. Fifty-three chemotherapy cycles were administered to the 17 patients treated (median, 3 cycles/patient). No complete responses, 1 partial response, 8 stable diseases and 8 progressions were noted. Toxocity was acceptable and no treatment-related deaths occurred. Actuarial median survival was 6 months. In this study, a combination of full doses of epirubicin and ifosfamide did not prove to be active in malignant mesothelioma.",
author = "Magri, {M. D.} and S. Foladore and A. Veronesi and C. Serra and M. Nicotra and M. Tommasi and G. Grandi and S. Monfardini and C. Bianchi",
year = "1992",
language = "English",
volume = "3",
pages = "237--238",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - Treatment of malignant mesothelioma with epirubicin and ifosfamide

AU - Magri, M. D.

AU - Foladore, S.

AU - Veronesi, A.

AU - Serra, C.

AU - Nicotra, M.

AU - Tommasi, M.

AU - Grandi, G.

AU - Monfardini, S.

AU - Bianchi, C.

PY - 1992

Y1 - 1992

N2 - From May 1988 to March 1990, 17 consecutive patients with histologically proven malignant mesothelioma were treated with epirubicin 75 mg/sqm i.v. on day 1 and ifosfamide 1.8 gr/sqm/day i.v. from day 1-5. Treatment was repeated every 3 weeks until progression. Fifty-three chemotherapy cycles were administered to the 17 patients treated (median, 3 cycles/patient). No complete responses, 1 partial response, 8 stable diseases and 8 progressions were noted. Toxocity was acceptable and no treatment-related deaths occurred. Actuarial median survival was 6 months. In this study, a combination of full doses of epirubicin and ifosfamide did not prove to be active in malignant mesothelioma.

AB - From May 1988 to March 1990, 17 consecutive patients with histologically proven malignant mesothelioma were treated with epirubicin 75 mg/sqm i.v. on day 1 and ifosfamide 1.8 gr/sqm/day i.v. from day 1-5. Treatment was repeated every 3 weeks until progression. Fifty-three chemotherapy cycles were administered to the 17 patients treated (median, 3 cycles/patient). No complete responses, 1 partial response, 8 stable diseases and 8 progressions were noted. Toxocity was acceptable and no treatment-related deaths occurred. Actuarial median survival was 6 months. In this study, a combination of full doses of epirubicin and ifosfamide did not prove to be active in malignant mesothelioma.

UR - http://www.scopus.com/inward/record.url?scp=0026574075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026574075&partnerID=8YFLogxK

M3 - Article

C2 - 1586623

AN - SCOPUS:0026574075

VL - 3

SP - 237

EP - 238

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -